Your browser doesn't support javascript.
loading
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Houot, Roch; Cartron, Guillaume; Bijou, Fontanet; de Guibert, Sophie; Salles, Gilles A; Fruchart, Christophe; Bouabdallah, Krimo; Maerevoet, Marie; Feugier, Pierre; Le Gouill, Steven; Tilly, Hervé; Casasnovas, Rene-Olivier; Moluçon-Chabrot, Cécile; Van Den Neste, Eric; Zachee, Pierre; Andre, Marc; Bonnet, Christophe; Haioun, Corinne; Van Hoof, Achiel; Van Eygen, Koen; Molina, Lysiane; Nicolas-Virelizier, Emmanuelle; Ruminy, Philippe; Morschhauser, Franck.
Afiliação
  • Houot R; Department of Clinical Hematology, University Hospital of Rennes, Inserm 0203, University of Rennes, Rennes, France.
  • Cartron G; Department of Clinical Hematology, University Hospital of Montpellier, UMR CNRS 5235, University of Montpellier, Montpellier, France.
  • Bijou F; French Blood Institute, Bordeaux, France.
  • de Guibert S; Department of Clinical Hematology, University Hospital of Rennes, Inserm 0203, University of Rennes, Rennes, France.
  • Salles GA; Department of Hematology, Centre Hospitalier Lyon-Sud, Pierre Benite, France.
  • Fruchart C; Institut d'Hématologie de Basse Normandie (IHBN), CHU, Caen, France.
  • Bouabdallah K; Haematology, CHU de Bordeaux, Bordeaux, France.
  • Maerevoet M; Hematology, Institut Jules Bordet, Bruxelles, Belgium.
  • Feugier P; CHU et INSERM 954, Nancy Université, Vandoeuvre Les Nancy, France.
  • Le Gouill S; Department of Hematology, Nantes University Hospital and UMR892 INSERM, Nantes, France.
  • Tilly H; Centre Henri Becquerel, Inserm U918, Université de Rouen, IRIB, Rouen, France.
  • Casasnovas RO; Hematology, University Hospital, Dijon, France.
  • Moluçon-Chabrot C; Hematology Department, CHU Clermont Ferrand, Clermont-Ferrand, France.
  • Van Den Neste E; Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Zachee P; AZ GROENINGE, Kortrijk, Belgium.
  • Andre M; Hematology Department, CHU UCL NAMUR, Yvoir, Belgium.
  • Bonnet C; Clinical Hematology, CHU University of Liège, Liège, Belgium.
  • Haioun C; Hôpital Henri Mondor, Unité Hémopathies Lymphoide, Créteil, France.
  • Van Hoof A; General Hospital St-Jan, Brugge, Belgium.
  • Van Eygen K; ZNA Stuivenberg, Antwerp, Belgium.
  • Molina L; Hematology, CHU de Grenoble, Grenoble, France.
  • Nicolas-Virelizier E; Hematology Department, Centre Léon Bérard, Lyon, France.
  • Ruminy P; Centre Henri Becquerel, Inserm U918, Université de Rouen, IRIB, Rouen, France.
  • Morschhauser F; Université de Lille/ hopital Claude Huriez, Lille, France. franck.morschhauser@chru-lille.fr.
Leukemia ; 33(3): 776-780, 2019 03.
Article em En | MEDLINE | ID: mdl-30291335
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article